Situated in Sydney’s Macquarie Park and built to pharmaceutical specifications, Recce and its experimental anti-infective formulations are produced in its wholly owned, automated manufacturing facility with existing output of 500 doses per hour at a 99.9% product yield.

Recce has demonstrated manufacturing quality and volume capabilities for RECCE® 327’s indicated first in-human clinical trials.

The U.S. Food and Drug Administration (FDA) awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

img 1
img 0 3
img 2

Sign up for news and updates

Receive news and information direct to your inbox.